Engineered catalytic RNA and DNA: New biochemical tools for drug discovery and design

American Journal of PharmacoGenomics

Volumn 3, Issue 2, 2003, Pages 131-144

  Steele, David ^a   Kertsburg, Alexis ^a   Soukup, Garrett A ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOZYME; BCR ABL PROTEIN; DEOXYRIBOZYME; DNA; HEPTAZYME; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PEGINTERFERON ALPHA2B; PEPTIDYLTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIBONUCLEASE P; RIBOSOME RNA; RIBOZYME; RNA; TRANSFER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ALLOSTERISM; BIOENGINEERING; BIOTECHNOLOGY; CATALYST; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DNA CLEAVAGE; DRUG DESIGN; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; GENOMICS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LUNG CANCER; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE; RNA DEGRADATION;

ANIMALS; DNA, CATALYTIC; DRUG DESIGN; GENETIC ENGINEERING; HUMANS; RNA, CATALYTIC; TECHNOLOGY, PHARMACEUTICAL;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0038352215     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200303020-00006     Document Type: Review

References (191)

1. Meli M, Albert-Fournier B, Maurel MC. Recent findings in the modern RNA world. Int Microbiol 2001; 4: 5-11
2. Kruger K, Grabowski PJ, Zaug AJ, et al. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982; 31: 147-57
3. Guerrier-Takada C, Gardiner K, Marsh T, et al. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 1983; 35: 849-57
4. Joyce GF. The antiquity of RNA-based evolution. Nature 2002; 418: 214-21
5. Newman A. Molecular biology: RNA enzymes for RNA splicing. Nature 2001; 413: 695-6
6. Moore PB, Steitz TA. The involvement of RNA in ribosome function. Nature 2002; 418: 229-35
7. Symons RH. Small catalytic RNAs. Annu Rev Biochem 1992; 61: 641-71
8. Forster AC, Symons RH. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 1987; 49: 211-20
9. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328: 596-600
10. Hampel A, Tritz R. RNA catalytic properties of the minimum (-)sTRSV sequence. Biochemistry 1989; 28: 4929-33
11. Sharmeen L, Kuo MTP, Dinter-Gottlieb G, et al. Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage. J Virol 1988; 62: 2674-9
12. Saville BJ, Collins RA. A site-specific self-cleavage reaction performed by a novel RNA in neurospora mitochondria. Cell 1990; 61: 685-96
13. Peebles CL, Perlman PS, Mecklenburg KL, et al. A self-splicing RNA excises an intron lariat. Cell 1986; 44: 213-23
14. Van der Veen R, Arnberg AC, Van der Horst G, et al. Excised group II introns in yeast mitochondria are lariats and can be formed by self-splicing in vitro. Cell 1986; 44: 225-34
15. Yean SL, Wuenschell G, Termini J, et al. Metal-ion coordination by U6 small nuclear RNA contributes to catalysis in the spliceosome. Nature 2000; 408: 881-4
16. Valadkhan S, Manley JL. Splicing-related catalysis by protein-free snRNAs. Nature 2001; 413: 701-7
17. Noller HF, Hoffarth V, Zimniak L. Unusual resistance of peptidyl transferase to protein extraction procedures. Science 1992; 256: 1416-9
18. Nissen P, Hansen J, Ban N, et al. The structural basis of ribosome activity in peptide bond synthesis. Science 2000, 930
19. Cannone JJ, Subramanian S, Schnare MN, et al. The comparative RNA Web (CRW) Site: an online database of comparative sequence and structure information for ribosomal, intron, and other RNAs. BMC Bioinformatics 2002; 3: 2
20. Cech TR. Self-splicing of group I introns. Annu Rev Biochem 1990; 59: 543-68
21. Bonen L, Vogel J. The ins and outs of group II introns. Trends Genet 2001; 17: 322-31
22. Newman A. RNA splicing. Curr Biol 1998; 8 (25): 903-5
23. Ban N, Nissen P, Hansen J, et al. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science 2000; 289: 905-20
24. Wimberly BT, Brodersen DE, Clemons WM, et al. Structure of the 30S ribosomal subunit. Nature 2000; 407: 327-39
25. Yusupov MM, Yusupova GZ, Baucom A, et al. Crystal structure of the ribosome at 5.5 Å resolution. Science 2001; 292: 883-96
26. Wilson DS, Szostak JW. In vitro selection of functional nucleic acids. Annu Rev Biochem 1999; 68: 611-47
27. Jaschke A. Artificial ribozymes and deoxyribozymes. Curr Opin Struct Biol 2001; 11: 321-6
28. Ekland EH, Bartel DP. RNA-catalysed RNA polymerization using nucleoside triphosphates. Nature 1996; 382: 373-6
29. Johnston WK, Unrau PJ, Lawrence MS, et al. RNA-catalyzed RNA polymerization: accurate and general RNA-templated primer extension. Science 2001; 292: 1319-25
30. McGinness KE, Wright MC, Joyce GF. Continuous in vitro evolution of a ribozyme that catalyzes three successive nucleotidyl addition reactions. Chem Biol 2002; 9: 585-96
31. Tarasow TM, Tarasow SL, Eaton BE. RNA-catalysed carbon-carbon bond formation. Nature 1997; 389: 54-7
32. Seelig B, Jaschke A. A small catalytic RNA motif with Diels-Alderase activity. Chem Biol 1999; 6: 167-76
33. Osborne SE, Ellington AD. Nucleic acid selection and the challenge of combinatorial chemistry. Chem Rev 1997; 97: 349-70
34. Gold L, Polinsky B, Uhlenbeck O, et al. Diversity of oligonucleotide functions. Annu Rev Biochem 1995; 64: 763-97
35. Breaker RR. In vitro selection of catalytic polynucleotides. Chem Rev 1997; 97: 371-90
36. Williams KP, Bartel DP. In vitro selection of catalytic RNA. Nucleic Acids Mol Biol 1996; 10: 367-81
37. 2+. Biochemistry 1992; 31: 3887-95
38. 2+-dependent self-cleaving ribozymes. EMBO J 1995; 14: 4551-7
39. Jayasena VK, Gold L. In vitro selection of self-cleaving RNAs with a low pH optimum. Proc Natl Acad Sci U S A 1997; 94: 10612-7
40. Vaish NK, Heaton PA, Fedorova O, et al. In vitro selection of a purine nucleotidespecific hammerhead-like ribozyme. Proc Natl Acad Sci U S A 1998; 95: 2158-62
41. Tang J, Breaker RR. Structural diversity of self-cleaving ribozymes. Proc Natl Acad Sci U S A 2000; 97: 5784-9
42. Beaudry A, DeFoe J, Zinnen S, et al. In vitro selection of a novel nuclease-resistant RNA phosphodiesterase. Chem Biol 2000; 7: 323-34
43. Zinnen SP, Domenico K, Wilson M, et al. Selection, design, and characterization of a new potentially therapeutic ribozyme. RNA 2002; 8: 214-28
44. Breaker RR, Joyce GF. A DNA enzyme that cleaves RNA. Chem Biol 1994; 1: 223-9
45. 2+-dependent RNA phosphoesterase activity. Chem Biol 1995; 2: 655-60
46. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci U S A 1997; 94: 4262-6
47. Li J, Zheng W, Kwon AH, et al. In vitro selection and characterization of a highly efficient Zn(II)-dependent RNA-cleaving deoxyribozyme. Nucleic Acids Res 2000; 28: 481-8
48. Feldman AR, Sen D. A new and efficient DNA enzyme for the sequence-specific cleavage of RNA. J Mol Biol 2001; 313: 283-94
49. Michienzi A, Rossi JJ. Intracellular applications of ribozymes. Methods Enzymol 2001; 341: 581-96
50. Uhlmann E, Peyman A. Antisense oligonucleotides: a new therapeutic principle. Chem Rev 1990; 90: 543-84
51. Usman N, Blatt LM. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest 2000; 106: 1197-202
52. Beigelman L, McSwiggen JA, Draper KG, et al. Chemical modification of hammerhead ribozymes: catalytic activity and nuclease resistance. J Biol Chem 1995; 270: 25702-8
53. Sioud M, Leirdal M. Design of nuclease resistant protein kinase Cα DNA enzymes with potential therapeutic application. J Mol Biol 2000; 296: 937-47
54. Amarzguioui M, Brede G, Babaie E, et al. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Nucleic Acids Res 2000; 28: 4113-24
55. Scherr M, Rossi JJ, Sczakiel G, et al. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res 2000; 28: 2455-61
56. Birikh KR, Berlin YA, Soreq H, et al. Probing accessible sites for ribozymes on human acetylcholinesterase RNA. RNA 1997; 3: 429-37
57. Scherr M, Rossi JJ. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res 1998; 26: 5079-85
58. Scherr M, Reed M, Huang CF, et al. Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase. Mol Ther 2000; 2: 26-38
59. Pan WH, Devlin HF, Kelley C, et al. A selection system for identifying accessible sites in target RNAs. RNA 2001; 7: 610-21
60. Lieber A, Strauss M. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol 1995; 15: 540-51
61. Sriram B, Banerjea AC. In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression. Biochem J 2000; 352: 667-73
62. Warashina M, Kuwabara T, Kata Y, et al. RNA-protein hybrid ribozymes that efficiently cleave any mRNA independently of the structure of the target RNA. Proc Natl Acad Sci U S A 2001; 98: 5572-7
63. Kawasaki H, Taira K. Identification of genes by hybrid ribozymes that couple cleavage activity with the unwinding activity of an endogenous RNA helicase. EMBO Rep 2002; 3: 443-50
64. Denman RB, Smedman M, Ju W, et al. Ribozyme mediated degradation of betaamyloid peptide precursor mRNA in COS-7 cells. Nucleic Acids Res 1994; 22: 2375-82
65. Denman RB, Smedman M, Abraham M, et al. Facilitated reduction of betaamyloid peptide precursor by synthetic oligonucleotides in COS-7 cells expressing a hammerhead ribozyme. Arch Biochem Biophys 1997; 348: 82-90
66. Flory CM, Pavco PA, Jarvis TC, et al. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc Natl Acad Sci U S A 1996; 93: 754-8
67. Irminger-Finger I, Soriano JV, Vaudan G, et al. In vitro repression of Brca1-associated RING domain gene, Bard1, induces phenotypic changes in mammary epithelial cells. J Cell Biol 1998; 143: 1329-39
68. Tokunaga T, Tsuchida T, Kijima H, et al. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br J Cancer 2000; 83: 833-9
69. Soeth E, Wirth T, List HJ, et al. Controlled ribozyme targeting demonstrates an antiapoptotic effect of carcinoembryonic antigen in HT29 colon cancer cells. Clin Cancer Res 2001; 7: 2022-30
70. Yokoyama Y, Wan X, Shinohara A, et al. Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma cells. Hum Cell 2001; 14: 223-31
71. Scanlon KJ, Jiao L, Funato T, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci U S A 1991; 88: 10591-5
72. Sioud M, Natvig JB, Forre O. Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J Mol Biol 1992; 223: 831-5
73. Czubayko F, Riegel AT, Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem 1994; 269: 21358-63
74. Kobayashi H, Dorai T, Holland JF, et al. Reversal of drug sensitivity in multidrugresistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res 1994; 54: 1271-5
75. Feng M, Cabrera G, Deshane J, et al. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55: 2024-8
76. Czubayko F, Downing SG, Hsieh SS, et al. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther 1997; 4: 943-9
77. Ma M, Benimetskaya L, Lebedeva I, et al. Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences. Nat Biotechnol 2000; 18: 58-61
78. Parry TJ, Cushman C, Gallegos AM, et al. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res 1999; 27: 2569-77
79. Pavco PA, Bouhana KS, Gallegos AM, et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000; 6: 2094-103
80. Hatanaka H, Abe Y, Naruke M, et al. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme. Anticancer Res 2001; 21: 879-85
81. Liu C, Cheng R, Sun LQ, et al. Suppression of platelet-type 12-lypoxygenase activity in human erythroleukemia cells by an RNA-cleaving DNAzyme. Biochem Biophys Res Commun 2001; 284: 1077-82
82. Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001; 3: 141-6
83. Cieslak M, Niewiarowska J, Nawrot M, et al. DNAzymes to β1 and β3 mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. J Biol Chem 2002; 277: 6779-87
84. Leirdal M, Sioud M. Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells. Br J Cancer 1999; 80: 1558-64
85. Kanazawa Y, Ohkawa K, Ueda K, et al. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 1996; 225: 570-6
86. Oshika Y, Nakamura M, Tokunaga T, et al. Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). Eur J Cancer 2000; 36: 2390-6
87. Kashani-Sabet M, Funato T, Florenes VA, et al. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994; 54: 900-2
88. Czubayko F, Schulte AM, Berchem GJ, et al. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci U S A 1996; 93: 14753-8
89. Maelandsmo GM, Hovig E, Skrede M, et al. Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 1996; 56: 5490-8
90. Yokoyama Y, Morishita S, Takahashi Y, et al. Modulation of c-fms protooncogene in an ovarian carcinoma cell line by a hammerhead ribozyme. Br J Cancer 1997; 76: 977-82
91. Chen S, Song CS, Lavrovsky Y, et al. Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol 1998; 12: 1558-66
92. Dorai T, Perlman H, Walsh K, et al. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int J Cancer 1999; 82: 846-52
93. Xu ZD, Oey L, Mohan S, et al. Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells. Endocrinology 1999; 140: 2134-44
94. Benedict CM, Pan W, Loy SE, et al. Triple ribozyme-mediated down-regulation of the retinoblastoma gene. Carcinogenesis 1998; 19: 1223-30
95. De Young MB, Kincade-Denker J, Boehm CA, et al. Functional characterization of ribozymes expressed using U1 and T7 vectors for the intracellular cleavage of ANF mRNA. Biochemistry 1994; 33: 12127-38
96. Macejak DG, Lin H, Webb S, et al. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo. J Virol 1999; 73: 7745-51
97. Frimerman A, Welch PJ, Jin X, et al. Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model. Circulation 1999; 99: 697-703
98. Sun LQ, Cairns MJ, Gerlach WL, et al. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J Biol Chem 1999; 274: 17236-41
99. Perlman H, Sata M, Krasinski K, et al. Adenovirus-encoded hammerhead ribozyme to Bcl-2 inhibits neointimal hyperplasia and induces vascular smooth muscle cell apoptosis. Cardiovasc Res 2000; 45: 570-8
100. Gu JL, Pei H, Thomas L, et al. Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries. Circulation 2001; 103: 1446-52
101. Khachigian LM, Fahmy RG, Zhang G, et al. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. J Biol Chem 2002; 277: 22985-91
102. Lowe HC, Chesterman CN, Khachigian LM. Catalytic antisense DNA molecules targeting erg-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. Thromb Haemost 2002; 87: 134-40
103. Efrat S, Leiser M, Wu YJ, et al. Ribozyme-mediated attenuation of pancreatic beta-cell glucokinase expression in transgenic mice results in impaired glucoseinduced insulin secretion. Proc Natl Acad Sci U S A 1994; 91: 2051-5
104. Goila R, Banerjea AC. Inhibition of hepatitis B virus X gene expression by novel DNA enzymes. Biochem J 2001; 353: 701-8
105. Lee PA, Blatt LM, Blanchard KS, et al. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 2000; 32: 640-6
106. Macejak DG, Jensen KL, Jamison SF, et al. Inhibition of hepatitis C virus (HCV)RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 2000; 31: 769-76
107. Chen CJ, Banerjea AC, Harmison GG, et al. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication: potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 1992; 20: 4581-9
108. Ojwang JO, Hampel A, Looney DJ, et al. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci U S A 1992; 89: 10802-6
109. Yu M, Ojwang J, Yamada O, et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993; 90: 6340-4
110. Zhou C, Bahner IC, Larson GP, et al. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994; 149: 33-9
111. Sun LQ, Pyati J, Smythe J, et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci U S A 1995; 92: 7272-6
112. Sun LQ, Wang L, Gerlach WL, et al. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res 1995; 23: 2909-13
113. Michienzi A, Prislei S, Bozzoni I. U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. Proc Natl Acad Sci U S A 1996; 93: 7219-24
114. Heusch M, Kraus G, Johnson P, et al. Intracellular immunization against SIVmac utilizing a hairpin ribozyme. Virology 1996; 216: 241-4
115. Larsson S, Hotchkiss G, Su J, et al. A novel ribozyme target site located in the HIV-1 nef open reading frame. Virology 1996; 219: 161-9
116. Zhou C, Bahner I, Rossi JJ, et al. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition. Antisense Nucleic Acid Drug Dev 1996; 6: 17-24
117. Bauer G, Valdez P, Kearns K, et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factormobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 1997; 89: 2259-67
118. Wang L, Witherington C, King A, et al. Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum Gene Ther 1998; 9: 1283-91
119. Dash BC, Harikrishnan TA, Goila R, et al. Targeted cleavage of HIV-1 envelope gene by a DNA enzyme and inhibition of HIV-1 envelope-CD4 mediated cell fusion. FEBS Lett 1998; 431: 395-9
120. Wong-Staal F, Poeschla EM, Looney DJ. A controlled, phase I clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 1998; 9: 2407-25
121. Amado RG, Mitsuyasu RT, Symonds G, et al. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 1999; 10: 2255-70
122. Zhang X, Xu Y, Ling H, et al. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme. FEBS Lett 1999; 458: 151-6
123. Bai J, Rossi J, Akkina R. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy. AIDS Res Hum Retroviruses 2001; 17: 385-99
124. Kraus G, Geffin R, Spruill G, et al. Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. Proc Natl Acad Sci U S A 2002; 99: 3406-11
125. Yen L, Strittmatter SM, Kalb RG. Sequence-specific cleavage of Huntington mRNA by catalytic DNA. Ann Neurol 1999; 46: 366-73
126. Mahieu M, Deschuyteneer R, Forget D, et al. Construction of a ribozyme directed against human interleukin-6 mRNA: evaluation of its catalytic activity in vitro and in vivo. Blood 1994; 84: 3758-65
127. Tang XB, Hobom G, Luo D. Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J Med Virol 1994; 42: 385-95
128. Plehn-Dujowich D, Altman S. Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P. Proc Natl Acad Sci U S A 1998; 95: 7327-32
129. Toyoda T, Imamura Y, Takaku H, et al. Inhibition of influenza virus replication in cultured cells by RNA-cleaving DNA enzyme. FEBS Lett 2000; 481: 113-6
130. Kozu T, Sueoka E, Okabe S, et al. Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA. J Cancer Res Clin Oncol 1996; 122: 254-6
131. Szyrach M, Munchberg FE, Riehle H, et al. Cleavage of AML1/MTG8 by asymmetric hammerhead ribozymes. Eur J Biochem 2001; 268: 3550-7
132. Shore SK, Nabissa PM, Reddy EP. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 proteinkinase activity. Oncogene 1993; 8: 3183-8
133. Snyder DS, Wu Y, Wang JL, et al. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 1993; 82: 600-5
134. Kuwabara T, Warashina M, Tanabe T, et al. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Mol Cell 1998; 2: 617-27
135. Wu Y, Yu L, McMahon R, et al. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther 1999; 10: 2847-57
136. Cobaleda C, Sanchez-Garcia I. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. Blood 2000; 95: 731-7
137. Hubinger G, Schmid M, Linortner S, et al. Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. Exp Hematol 2001; 29: 1226-35
138. Iversen PO, Sioud M. Modulation of granulocyte-macrophage colony-stimulating factor gene expression by a tumor necrosis factor specific ribozyme in juvenile myelomonocytic leukemic cells. Blood 1998; 92: 4263-8
139. Suwanai H, Matsushita H, Kobayashi H, et al. A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: improved design of maxizymes against PML/RARα mRNA. Int J Oncol 2002; 20: 127-30
140. Lewin AS, Drenser KA, Hauswirth WW, et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med 1998; 4: 967-71
141. Lieber A, He CY, Polyak SJ, et al. Elimination of hepatitic C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996; 70: 8782-91
142. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 98: 2720-8
143. Welch PJ, Tritz R, Yei S, et al. A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 1996; 3: 994-1001
144. Macejak DG, Jensen KL, Pavco PA, et al. Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. J Viral Hepat 2001; 8: 400-5
145. Sandberg JA, Rossi S, Gordon GS, et al. Safety analysis of a phase I study of HEPTAZYME™, a nuclease resistant ribozyme targeting hepatitis C (HCV) RNA. Boulder (CO): Ribozyme Pharmaceuticals Inc., 2001 (Data on file)
146. Sandberg JA, Parker VP, Blanchard KS, et al. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME™) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey. Antisense Nucleic Acid Drug Dev 2000; 10: 153-62
147. Weng DE, Weiss P, Kellacky C, et al. A phase I/II study of repetitive dose Angiozyme™, a ribozyme targeting the flt-1 receptor for VEGF. Proceedings of the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy; 2000 Nov 7;, Amsterdam
148. Cobaleda C, Sanchez-Garcia I. RNase P: from biological function to biotechnological application. Trends Biotechnol 2001; 19: 406-11
149. Dunn W, Trang P, Khan U, et al. RNase P-mediated inhibition of cytomegalovirus protease expression and viral DNA encapsidation by oligonucleotide external guide sequences. Proc Natl Acad Sci U S A 2001; 98: 14831-6
150. Watanabe T, Sullenger BA. RNA repair: a novel approach to gene therapy. Adv Drug Deliv Rev 2000; 44: 109-18
151. Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. Nature 1994; 371: 619-22
152. Kohler U, Ayre BG, Goodman HM, et al. Trans-spicing ribozymes for targeted gene delivery. J Mol Biol 1999; 285: 1935-50
153. Zarrinkar PP, Sullenger BA. Optimizing the substrate specificity of a group I intron ribozyme. Biochemistry 1999; 38: 3426-32
154. Lan N, Howrey RP, Lee SW, et al. Ribozyme-mediated repair of sickle β-globin mRNA in erythrocyte precursor. Science 1998; 280: 1593-6
155. Phylactou LA, Darrah C, Wood MJ. Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nat Genet 1998; 18: 378-81
156. Watanabe T, Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci U S A 2000; 97: 8490-4
157. Eskes R, Yang J, Lambowitz AM, et al. Mobility of yeast mitochondrial group II introns: engineering a new site specificity and retrohoming via full reverse splicing. Cell 1997; 88: 865-74
158. Cousineau B, Smith D, Lawrence-Cavanagh S, et al. Retrohoming of a bacterial group II intron: mobility via complete reverse splicing, independent of homologous DNA recombination. Cell 1998; 94: 451-62
159. Guo H, Karberg M, Long M, et al. Group II introns designed to insert into therapeutically relevant DNA target sites in human cells. Science 2000; 289: 452-7
160. Kawasaki H, Onuki R, Suyama E, et al. Identification of genes that function in the TNF-α-mediated apoptotic pathway using randomized hybrid ribozyme libraries. Nat Biotechnol 2002; 20: 376-80
161. Soukup GA, Breaker RR. Nucleic acid molecular switches. Trends Biotechnol 1999; 17: 469-76
162. Breaker RR. Engineered allosteric ribozymes as biosensor components. Curr Opin Biotechnol 2002; 13: 31-9
163. Tang J, Breaker RR. Rational design of allosteric ribozymes. Chem Biol 1997; 4: 453-9
164. Soukup GA, Breaker RR. Engineering precision RNA molecular switches. Proc Natl Acad Sci U S A 1999; 96: 3584-9
165. Koizumi M, Soukup GA, Kerr JN, et al. Allosteric selection of ribozymes that respond to the second messengers cGMP and cAMP. Nat Struct Biol 1999; 6: 1062-71
166. Piganeau N, Jenne A, Thuillier V, et al. An allosteric ribozyme regulated by doxycycline. Angew Chem Int Ed Engl 2000; 39: 4369-73
167. Robertson MP, Ellington AD. In vitro selection of nucleoprotein enzymes. Nat Biotechnol 2001; 19: 650-5
168. Soukup GA, DeRose EC, Koizumi M, et al. Generating new ligand-binding RNAs by affinity maturation and disintegration of allosteric ribozymes. RNA 2001; 7: 524-36
169. Robertson MP, Ellington AD. In vitro selection of an allosteric ribozyme that transduces analytes to amplicons. Nat Biotechnol 1999; 17: 62-6
170. Soukup GA, Emilsson GAM, Breaker RR. Altering molecular recognition of RNA aptamers by allosteric selection. J Mol Biol 2000; 298: 623-32
171. Robertson MP, Ellington AD. Design and optimization of effector-activated ribozyme ligases. Nucleic Acids Res 2000; 28: 1751-9
172. Kertsburg A, Soukup GA. A versatile communication module for controlling RNA folding and catalysis. Nucleic Acids Res 2002; 30: 4599-606
173. Levy M, Ellington AD. ATP-dependent allosteric DNA enzymes. Chem Biol 2002; 9: 417-26
174. Wang DY, Lai BH, Sen D. A general strategy for effector-mediated control of RNA-cleaving ribozymes and DNA enzymes. J Mol Biol 2002; 318: 33-43
175. Hartig JS, Najifi-Shoushtari SH, Grune I, et al. Protein-dependent ribozymes report molecular interactions in real time. Nat Biotechnol 2002: 20: 717-22
176. Vaish NK, Dong F, Andrews L, et al. Monitoring post-translational modification of proteins with allosteric ribozymes. Nat Biotechnol 2002; 20: 810-5
177. Wang DY, Sen D. Rationally designed allosteric variants of hammerhead ribozymes responsive to the HIV-1 Tat protein. Comb Chem High Throughput Screen 2002; 5: 301-12
178. Kuwabara T, Warashina M, Tanabe T, et al. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Mol Cell 1998; 2: 617-27
179. Tanabe T, Takata I, Kuwabara T, et al. Maxizymes, novel allosterically controllable ribozymes, can be designed to cleave various substrates. Biomacromolecules 2002; 1: 108-17
180. Wang DY, Sen D. A novel mode of regulation of an RNA-cleaving DNAzyme by effectors that bind to both enzyme and substrate. J Mol Biol 2001; 310: 723-34
181. Burke DH, Ozerova ND, Nilsen-Hamilton M. Allosteric hammerhead ribozyme TRAPs. Biochemistry 2002; 41: 6588-94
182. Wang DY, Lai BH, Feldman AR, et al. A general approach for the use of oligonucleotide effectors to regulate the catalysis of RNA-cleaving ribozymes and DNAzymes. Nucleic Acids Res 2002; 30: 1735-42
183. Stojanovic MN, de Prada P, Landry DW. Homogeneous assays based on deoxyribozyme catalysis. Nucleic Acids Res 2000; 28: 2915-8
184. Frauendorf C, Jaschke A. Detection of small organic analytes by fluorescing molecular switches. Bioorg Med Chem 2001; 9: 2521-4
185. Seetharaman S, Zivarts M, Sudarsan N, et al. Immobilized RNA switches for the analysis of complex chemical and biological mixtures. Nat Biotechnol 2001; 19: 336-41
186. Tanabe T, Kuwabara T, Warashina M, et al. Oncogene inactivation in a mouse model. Nature 2000; 406: 473-4
187. Kuwabara T, Tanabe T, Warashina M, et al. Allosterically controllable maxizymemediated suppression of progression of leukemia in mice. Biomacromolecules 2001; 2: 1220-8
188. Cairns MJ, King A, Sun LQ. Nucleic acid mutation analysis using catalytic DNA. Nucleic Acids Res 2000; 28: E9
189. Todd AV, Fuery CJ, Impey HL, et al. DzyNA-PCR: use of DNAzymes to detect and quantify nucleic acid sequences in a real-time fluorescent format. Clin Chem 2000; 46: 625-30
190. Hannon GJ. RNA interference. Nature 2002; 418: 244-51
191. Tuschl T. Expanding small RNA interference. Nat Biotechnol 2002; 20: 446-8